Evogene Ltd. Files May 2024 6-K Report

Ticker: EVGN · Form: 6-K · Filed: May 29, 2024 · CIK: 1574565

Sentiment: neutral

Topics: 6-K, foreign-private-issuer, disclosure

TL;DR

Evogene Ltd. filed its May 6-K, check the exhibits for updates.

AI Summary

Evogene Ltd. filed a Form 6-K on May 29, 2024, for the month of May 2024. The filing is a report of a foreign private issuer and includes Exhibit 99.1. Evogene Ltd. is incorporated in Israel and its fiscal year ends on December 31.

Why It Matters

This filing provides an update on Evogene Ltd.'s activities as a foreign private issuer, which is important for investors to stay informed about the company's ongoing operations and disclosures.

Risk Assessment

Risk Level: low — This filing is a routine report of a foreign private issuer and does not appear to contain significant new financial or operational information that would immediately impact risk.

Key Players & Entities

FAQ

What type of filing is this 6-K?

This is a Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934.

What is the company's SEC File Number?

The company's SEC File Number is 001-36187.

When was this filing submitted?

This filing was submitted on May 29, 2024.

What is the principal executive office address of Evogene Ltd.?

The principal executive office address is 13 Gad Feinstein Street, Park Rehovot, Rehovot 7638517, Israel.

What exhibit is attached to this 6-K filing?

Exhibit 99.1 is attached to this 6-K filing.

Filing Stats: 193 words · 1 min read · ~1 pages · Grade level 12.8 · Accepted 2024-05-29 07:00:16

Filing Documents

From the Filing

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of May 2024 Commission File Number: 001-36187 EVOGENE LTD. (Translation of Registrant's Name into English) 13 Gad Feinstein Street, Park Rehovot Rehovot 7638517, Israel (Address of principal executive offices) Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F. Form 20-F Form 40-F Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ____ Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ____ CONTENTS Attached hereto and incorporated by reference herein is the following exhibit: 99.1 Evogene Investor Presentation. Signature Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. Date: May 29, 2024 EVOGENE LTD. (Registrant) By: /s/ Yaron Eldad Yaron Eldad Chief Financial Officer

View Full Filing

View this 6-K filing on SEC EDGAR

View on Read The Filing